Global Lyophilization Services Market for Biopharmaceuticals (2022 to 2035) - by Type of Biologic Lyophilized, Type of Primary Packaging System and Key Geographies - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Lyophilization Services Market for Biopharmaceuticals by Type of Biologic Lyophilized, Type of Primary Packaging System and Key Geographies: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.
This report features an extensive study of companies engaged in offering lyophilization services for biopharmaceuticals. The study features an in-depth analysis of the key drivers and trends related to this domain.
Over the last decade, a steady rise has been observed in the annual number of approvals for various types of biologics (including monoclonal antibodies, cell therapies, recombinant proteins, vaccines and gene therapies). In addition, more than 8,000 biological therapeutics are currently being evaluated in clinical trials, being conducted across the globe. Evidently, biologics have emerged as one of the fastest growing segments in the pharmaceutical industry.
Driven by several advantages offered by biologics over small molecules (including high efficacy, target specificity and favorable safety profiles), the biopharmaceutical market is anticipated to witness continued and consistent growth over the next several years. However, there are a variety of challenges associated with such therapies.
For instance, biological drugs are inherently less stable as compared to small molecules and, therefore, more prone to physical and chemical degradation. In order to achieve longer and commercially viable shelf lives, players are actively adopting the lyophilization (also known as freeze-drying) technique; it enables the production of stable dry biopharmaceutical formulations. In this context, it is worth highlighting that around 50% of the currently approved biopharmaceuticals are injectables. Of these, about one third of the drug candidates are being lyophilized.
Setting up in-house lyophilization capabilities and operations is an expensive and time-consuming process, which requires specialized lyophilization equipment and expertise. Considering the high capital investment and technical / routine operations-related challenges associated with lyophilization of biopharmaceuticals, a growing number of biologic developers are outsourcing their lyophilization operations to qualified contract manufacturing organizations (CMOs) in order to leverage their capabilities and yield cost savings opportunities.
Presently, more than 105 contract manufacturers claim to have the required capabilities to offer lyophilization services for biotherapeutics. In addition, lyophilization service providers are entering into strategic alliances in order to consolidate their presence in this field and enhance existing capabilities to meet the growing demand for biologics. Driven by the increasing preference for outsourcing, continuous growth of the biological therapeutics pipeline and a steady rise in drug approvals, the lyophilization services market for biopharmaceuticals is likely to witness steady growth in the foreseen future.
Key Questions Answered
- Who are the key players engaged in offering lyophilization services for biopharmaceuticals?
- What is the relative competitiveness of lyophilization service providers for biopharmaceuticals?
- What type of partnership models are commonly adopted by stakeholders in this industry?
- What are the different types of expansion initiatives being undertaken by lyophilization service providers for biopharmaceuticals?
- What are the key market trends and driving factors that are likely to impact this market?
- How is the current and future market opportunity likely to be distributed across key segments?
Key Topics Covered:
2. EXECUTIVE SUMMARY
4. MARKET LANDSCAPE
5. BENCHMARK ANALYSIS
5.1. Chapter Overview
5.3. Benchmark Analysis: Peer Groups
6. COMPANY PROFILES: LYOPHILIZATION SERVICE PROVIDERS FOR BIOPHARMACEUTICALS IN NORTH AMERICA
6.1. Chapter Overview
6.2. Baxter BioPharma Solutions
6.4. Emergent BioSolutions
6.5. LSNE Contract Manufacturing
6.6. Lyophilization Technology
7. COMPANY PROFILES: LYOPHILIZATION SERVICE PROVIDERS FOR BIOPHARMACEUTICALS IN EUROPE
7.1. Chapter Overview
7.3. Coriolis Pharma
7.4. Northway Biotech
7.5. ProJect Pharmaceutics
7.6. Vetter Pharma
8. COMPANY PROFILES: LYOPHILIZATION SERVICE PROVIDERS FOR BIOPHARMACEUTICALS IN ASIA PACIFIC
8.1. Chapter Overview
8.2. BioZed Engineering
8.5. Samsung Biologics
8.6. WuXi Biologics
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Lyophilization Services for Biopharmaceuticals: List of Partnerships and Collaborations
10. RECENT EXPANSIONS
10.1. Chapter Overview
10.2. Lyophilization Services Market for Biopharmaceuticals: List of Recent Expansions
11. SURVEY ANALYSIS
11.1. Chapter Overview
11.2. Lyophilization Services Market for Biopharmaceuticals: List of Participating Companies
12. CASE STUDY I: LYOPHILIZATION CYCLE DEVELOPMENT AND OPTIMIZATION
12.1. Chapter Overview
12.2. Lyophilization Cycle Development
12.3. Lyophilization Cycle Optimization
12.4. Lyophilization Cycle Development and Optimization: List of Service Providers
13. CASE STUDY II: ALTERNATIVE APPROACHES TO LYOPHILIZATION
13.1. Chapter Overview
13.2. Alternative Approaches to Lyophilization
14. MARKET FORECAST AND OPPORTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Forecast Methodology and Key Assumptions
14.3. Global Lyophilization Services Market for Biopharmaceuticals, 2022-2035
14.4. Lyophilization Services Market for Biopharmaceuticals: Distribution by Type of Biologic Lyophilized, 2022 and 2035
14.5. Lyophilization Services Market for Biopharmaceuticals: Distribution by Type of Primary Packaging System, 2022 and 2035
14.6. Lyophilization Services Market for Biopharmaceuticals: Distribution by Geography, 2022 and 2035
15. CONCLUDING REMARKS
16. EXECUTIVE INSIGHTS
17. APPENDIX 1: TABULATED DATA
18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION
For more information about this report visit https://www.researchandmarkets.com/r/aagvj0
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900